author-photo

C. Mahier Aït-Oukhatar

12

Papers

152

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (47)
1556PCirculating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
434PBiomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
OA12.03 Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (10)
How to report toxicity associated with targeted therapies

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Lower risk of cutaneous squamous cell carcinomas induced by vemurafenib in non melanoma patients

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial

2013 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (31)
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

2012 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (11)
First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP)

2009 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (34)